Guanfacine Dosing Recommendations
For ADHD in children and adolescents, start guanfacine extended-release at 1 mg once daily and titrate weekly using weight-based dosing of approximately 0.1 mg/kg/day (maximum 4 mg/day), while for hypertension in adults, start immediate-release guanfacine at 1 mg at bedtime with most therapeutic effect achieved at this dose. 1, 2
ADHD Dosing (Extended-Release Formulation)
Standard Dosing Algorithm
- Starting dose: 1 mg once daily 1
- Titration: Use weight-based approach of 0.1 mg/kg as a rule of thumb 1
- Available strengths: 1,2,3, and 4 mg tablets 1
- Maximum dose: 4 mg/day (though higher weight-adjusted doses up to 0.12 mg/kg may provide additional benefit if tolerated) 3
- Administration: Once daily dosing 1
Important Considerations for ADHD
The evidence strongly supports weight-based dosing rather than arbitrary dose escalation. Data suggest doses >0.08 mg/kg but ≤0.12 mg/kg may provide additional clinical benefits if tolerated 3. However, the FDA-approved maximum remains 4 mg/day, which may be limiting for heavier adolescents requiring optimal weight-adjusted dosing.
Onset of effect: Unlike stimulants which work immediately, guanfacine requires 2-4 weeks to demonstrate treatment effects 1. This delayed onset is critical for patient counseling and adherence.
Hypertension Dosing (Immediate-Release Formulation)
Standard Dosing Algorithm
- Starting dose: 1 mg at bedtime to minimize somnolence 2
- Titration: If inadequate response after 3-4 weeks, may increase to 2 mg 2
- Maximum effective dose: Most effect seen at 1 mg; doses above 3 mg/day significantly increase adverse reactions 2
- Administration: Once daily at bedtime 2
Critical Dosing Nuance
The dose-response data reveal that higher doses (above 3 mg/day) add minimal blood pressure benefit but substantially increase adverse effects 2. This is a common prescribing pitfall—resist the temptation to escalate beyond 2-3 mg unless absolutely necessary.
Special Population Adjustments
Renal Impairment
Use the low end of the dosing range in patients with renal insufficiency 2. While plasma levels increase only slightly with renal impairment, clearance is reduced 2, 4. Importantly, guanfacine is poorly dialyzed, so patients on dialysis can receive usual doses 2. The drug undergoes significant non-renal elimination (approximately 50% metabolized), which compensates somewhat for reduced renal clearance 4.
CYP3A4 Drug Interactions
With Strong or Moderate CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin, fluconazole):
- Decrease guanfacine dose to 50% of the usual target dose 5
- Rationale: Moderate inhibitors increase guanfacine AUC by approximately 2-fold 5
With Strong or Moderate CYP3A4 Inducers (e.g., rifampicin, efavirenz):
- Consider titrating guanfacine up to double the usual target dose over 1-2 weeks 5
- Rationale: Moderate inducers can reduce guanfacine AUC to 33-58% of baseline 5
This is particularly important since guanfacine is primarily metabolized via CYP3A4 and excreted predominantly renally 1.
Critical Safety Warnings
Cardiovascular Monitoring
- Baseline: Obtain personal and family cardiac history, blood pressure, and heart rate 6
- During treatment: Monitor vital signs regularly as guanfacine causes dose-dependent decreases in blood pressure (average 1-4 mmHg) and heart rate (average decrease of 5 bpm in ADHD studies, up to 12 bpm reported) 6, 7
- Consider ECG: If cardiac risk factors present before initiating therapy 6
Discontinuation Protocol
Never abruptly discontinue guanfacine—taper the medication to avoid rebound hypertension 6, 2. While rebound is less frequent and delayed (2-4 days) compared to clonidine due to guanfacine's longer half-life, it can occur 2. Blood pressure typically returns to pretreatment levels gradually over 2-4 days 2.
Common Adverse Effects
Most frequent: somnolence, fatigue, dizziness, irritability, headache, bradycardia, hypotension, and abdominal pain 1, 6. Somnolence-related effects tend to resolve over time 8.
Formulation-Specific Pitfall
Critical prescribing error to avoid: Extended-release (for ADHD) and immediate-release (for hypertension) formulations are NOT interchangeable 9. A case report documented profound bradycardia and hypotension requiring PICU admission when a 6-year-old received immediate-release instead of extended-release formulation 9. Always verify the correct formulation is prescribed and dispensed.